Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs
Executive Summary
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.